The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Thierry Sornasse, Ph.D., AbbVie (Co-Chair)
David Fox, M.D., University of Michigan (Co-Chair) Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics Mark Allegretta, Ph.D., National MS Society Anne-Christine Bay-Jensen, Ph.D., Nordic Biosciences A/S Chip Beckwith, Ph.D., Standard Biotools Robert Benschop, Ph.D., Eli Lilly Anna Berdine, M.S., Alamar Biosciences Maria Bettinotti, Ph.D., Johns Hopkins University Preethi Chander, Ph.D., NIDCR/NIH Ananth Charya, M.D., NHLBI/NIH Li Chen, Ph.D., PharmaNest Laurence Cheng, M.D., Ph.D., Amgen Ronald Cheung, M.D., Ph.D., Jazz Pharmaceuticals Kelly Chun, Ph.D., LabCorp Janet Church, Sjögren’s Foundation Carolyn Cuff, Ph.D., Janssen Thomas Daly, M.D., Eli Lilly Sahar Dawisha, M.D., FDA/CDRH Betty Diamond, Ph.D., Feinstein Institute Renee Donahue, Ph.D., NIH/NCI Ed Driggers, Ph.D., General Metabolics Kellie Feck, Olink Carol Feghali-Bostwick, Ph.D., National Scleroderma Foundation Julie Fiore, M.D., Ph.D., Merck Dan Fitzpatrick, Ph.D., Amgen Thomas Fuerst, Ph.D., Clario Rebecca Fuldner, Ph.D., NIH/NIA Danielle Gerlag, M.D., UCB, Inc. Meryn Griffith, Ph.D., UCB, Inc. Mireia Guerau, PharmD, Ph.D., NIH/NIAID Christian Gomez, Ph.D., NIH/NHLBI Tim Hagerty, Tempus Kathy Hammitt, M.A., Sjogren’s Foundation Stephanie Hennek, Ph.D., PathAI Andrea Hooper, Ph.D, Regeneron Ewan Hunter, Oxford Biodynamics Andres Hurtado-Lorenzo, Crohn’s & Colitis Foundation Angelika Jahreis, Novartis Christina Jayson, Path AI Chao Jiang, Ph.D., NIAID/NIH Daniel Johnston, Ph.D., NIH/NICHD Kathy Jung, Ph.D., NIH/NIAAA Jason Kim, Ph.D., Arthritis Foundation Anjli Kukreja, Ph.D., Boehringher Ingelheim Stephen Laroux, Ph.D., AbbVie Steven Leonard, Johnson & Johnson |
David Martin, M.D., Pfizer
Russell McBride, Ph.D., MPH, Icahn School of Medicine at Mount Sinai Jeffrey Ming, M.D., Ph.D., Sanofi Andrea Mortera, Empatica Alan Moss, M.D,. Crohn’s & Colitis Foundation of America Raj Nair, Ph.D., FDA/CDER Nikolay Nikolov, M.D., FDA/CDER Heiyoung Park, Ph.D., NIAMS/NIH Jane Parnes, M.D., Amgen Brian Porter, M.D., Ph.D., M.P.H., M.B.A., Novartis Josh Porter, Olink Proteomics Rubio Punzalan, Ph.D., LabCorp John Reveille, M.D., University of Texas Health Science Center (Houston) Lisa Rider, M.D., NIH/NIEHS Mert Sahin, Ph.D., Durin Technologies Jane Salmon, M.D., Hospital for Special Surgery Johannes Scheid, M.D., Ph.D., Merck Adam Schiffenbauer, M.D., NIH/NIEHS Maggie Scully, Ph.D., Frederick National Laboratory for Cancer Research Susana A. Serrate-Sztein, M.D., NIH/NIAMS Vicki Shanmugam, MBBS, MRCP, FACR, CCD, NIH / OADR Diane Shevell, Ph.D., Novartis Glennda Smithson, Ph.D., Takeda Lisa Spain, Ph.D., NIH/NIDDK Emily Boyd Stormoen, Arthritis National Research Foundation Funda Suer, Ph.D., Durin Technologies Mark Tengowski, Ph.D., Clario Paresh Thakker, Ph.D., Takeda Mulualem Tilahun, DVM, Ph.D., NIH/NIA/DAB Candance Tingen, Ph.D., NIH/NICHD Danielle Townsley, M.D., MSc, Amgen Joe Wang, Ph.D., NIH/NIAAA Ilan Wapinski, Ph.D., Sanofi Michael Weisman, M.D., Stanford University Mary Wheatley, CAE, National Scleroderma Foundation Michael Whitfield, Ph.D., Dartmouth Geisel School of Medicine Joel Wommack, Ph.D., Standard Biotools Jennifer Yoon, Standard Biotools Jad Zoghbi, M.S., Biogen |